Halberd Corporation Files for Patent Protection on Covid-19 Extracorporeal Treatment Variation
Halberd Corp. (OTC PINK: HALB) announced the filing of a provisional patent for a new method aimed at eradicating Covid-19 from infected blood using an extracorporeal treatment process. The novel technique involves exposing blood to a specific radio frequency that targets a unique conjugate antibody designed to bind with the virus. This treatment reportedly presents fewer side effects compared to conventional methods. Halberd maintains its focus on complementary Covid-19 initiatives, including a nasal spray and rapid diagnostic tests.
- Filed a provisional patent for a novel extracorporeal treatment method for Covid-19.
- The new method aims to reduce side effects compared to traditional treatments.
- Exclusive rights to multiple Covid-19 treatment patent applications enhance market positioning.
- None.
JACKSON CENTER, PA / ACCESSWIRE / November 19, 2020 / Halberd Corp. (OTC PINK:HALB) reported the filing of a provisional patent application on a variation of Halberd's patented extracorporeal method to treat/eradicate Covid-19 from a patient's blood. By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects than with more conventional treatment regimens.
Halberd's provisional patent application, "Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus," discloses a unique application of extracorporeal exposure of virus-infected blood to a specifically created antibody which has been demonstrated to bind with the virus, but without deleterious side effects. This conjugate antibody/antigen pair is designed to react to an externally applied specific radio frequency which destroys the virus-antibody pair in real-time.
Dr. Mitchell S. Felder, inventor of this technology and consultant to Halberd Corporation's Scientific Advisory Board, stated, "A pathogen binding antibody binds to the target antigen and includes a moiety that reacts to a specific radio frequency. The result is the disease-causing pathogen is destroyed without further harm to the patient. This process could be similarly employed on any number of blood-borne diseases."
William A. Hartman, Chairman, President & CEO, added, "Of all the methods we have investigated, this seems to be the easiest and most effective in eliminating Covid-19 antigens. This would be intended to be administered in a hospital setting to those patients most adversely affected by Covid-19. The development of this technology will not interfere with, or otherwise delay, pursuit of our twin number one priorities -- nasal spray preventative and fluorescent antibody rapid diagnostic test."
The details of the Halberd-ASU research contract can be viewed here.
If you would like to be added to our email subscriber list, click here and submit the form.
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company's Articles of Incorporation here.
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus," and, "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans," "Nasal Spray to Prevent the Transmission of Covid-19," and "Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/617470/Halberd-Corporation-Files-for-Patent-Protection-on-Covid-19-Extracorporeal-Treatment-Variation
FAQ
What is Halberd's latest patent application regarding Covid-19?
How does Halberd's Covid-19 treatment work?
What are Halberd's plans after the patent filing?
What is the significance of Halberd holding multiple Covid-19 patents?
What stock symbol represents Halberd Corp.?
